Psoriasis Therapy in Real Life: The Need for Registries

Schmitt‐Egenolf, Marcus

doi:10.1159/000096196

Cited by 54 publications

(52 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A targeted intervention program may be needed in the management of patients with psoriasis, in order to identify and treat the above-mentioned disease. A register of psoriasis patients, such as offered by Schmitt-Egenolf [18], may help facilitate this task.Appropriate management of the metabolic syndrome may also play a role in the treatment of psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Association between Psoriasis and the Metabolic Syndrome

Cohen

Sherf²,

Vidavsky³

et al. 2008

Dermatology

255

230

View full text Add to dashboard Cite

Background: Previous reports have shown an association between inflammatory diseases such as systemic lupus erythematosus or rheumatoid arthritis and the metabolic syndrome. Recent data demonstrate that psoriasis is an inflammatory disease, suggesting that psoriasis may be one of the components of the metabolic syndrome. Objective: To assess the association between psoriasis and the metabolic syndrome. Methods: A cross-sectional study was performed utilizing the database of the Clalit Health Services. Case patients were defined as patients with a diagnosis of psoriasis vulgaris. Controls were randomly selected from the list of Clalit Health Services enrollees. The proportions of components of the metabolic syndrome (ischemic heart disease, hypertension, diabetes, obesity and dyslipidemia) were compared between case and control patients by univariate analyses. χ² tests were used to compare categorical parameters between the groups. Logistic and linear regression models served to measure the association between psoriasis and the metabolic syndrome. Results: The study included 16,851 patients with psoriasis and 48,681 controls. In the case group, there were 8,449 men (50.1%) and 8,402 women (49.9%), with a mean age of 42.7 years (SD = 20.3, range = 2–111). Diabetes mellitus was present in 13.8% of the patients with psoriasis as compared to 7.3% of the controls (p < 0.001). Hypertension occurred in 27.5% of the patients with psoriasis and in 14.4% of the controls (p < 0.001). Obesity was present in 8.4% of the patients with psoriasis as opposed to 3.6% of the controls (p < 0.001). Ischemic heart disease was observed in 14.2% of the patients with psoriasis as compared to 7.1% of the controls (p < 0.001). Multivariate models adjusting for age, gender and smoking status of the patients demonstrated that psoriasis was associated with the metabolic syndrome (OR = 1.3, 95% CI = 1.1–1.4), ischemic heart disease (OR = 1.1, 95% CI = 1.0–1.2), diabetes mellitus (OR = 1.2, 95% CI = 1.0–1.3), hypertension (OR = 1.3, 95% CI = 1.2–1.5) and obesity (OR = 1.7, 95% CI = 1.5–1.9). Limitations: The study is designed as a case-control study, thus an association alone was proven and not causality. Conclusion: Our findings demonstrate a possible association between psoriasis and the metabolic syndrome. Appropriate treatment of the metabolic syndrome may be an important part of the management of patients with psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between Psoriasis and the Metabolic Syndrome

Cohen

Sherf²,

Vidavsky³

et al. 2008

Dermatology

255

230

View full text Add to dashboard Cite

show abstract

“…Clinicians and patients have to make informed choices about traditional therapies such as methotrexate, ciclosporin and acitretin with their know toxicities, and more expensive biological therapies for which better evidence is available but safety remains uncertain. Trials of biologics only study short-term efficacy and safety particularly in comparison to placebo [3]. Questions remain as to the relative benefits and long-term safety of most of the agents used in the therapy of this chronic condition.…”

Section: Introductionmentioning

confidence: 99%

Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies

et al. 2012

View full text Add to dashboard Cite

Background: Large disease registries are the preferred method to assess long-term treatment safety. If psoriasis registries collaborate in a network, their power to assess safety is increased. Objective: To identify heterogeneity in psoriasis registries and methodological challenges for synthesising the data they provide. Methods: We surveyed the registries in PSONET and identified and addressed the challenges to collaborative analysis for the network in several round table meetings. Results: Eight out of 10 registries had a prospective comparator cohort with similar disease characteristics but not on biologics. Registries differed in the coding and validation or follow-up of adverse events and in the way they sampled their population. Fifteen challenges to registries collaborating were identified in the areas of operational governance, structural conduct, bias and analysis. Conclusions: Participation in PSONET, a network of psoriasis registries, helps identify and solve common issues, enhancing the individual registries, and provides larger sets of more powerful safety data in a diverse population. Challenges to interpreting data collectively include heterogeneity in sampling, variable penetration of biologics and compatibility of different datasets.

show abstract

“…PsoReg will provide a systematic but real-life picture of the diseased population in actual practice and can compensate for the inherent shortcomings of both randomized clinical trials and spontaneous reporting of side effects which have been discussed recently [1]. …”

Section: Introductionmentioning

confidence: 99%

PsoReg – The Swedish Registry for Systemic Psoriasis Treatment

Schmitt‐Egenolf¹

2007

Dermatology

Self Cite

View full text Add to dashboard Cite

With the introduction of new systemic drugs for the management of psoriasis, we felt an obligation in Sweden to establish a trusted tool to monitor their use. We formed PsoReg to create a solid, long-term database in order to analyze safety and effectiveness of different systemic psoriasis treatment regimens. PsoReg will provide information to help clinicians individualize therapy on a rational basis through evaluation of effectiveness and adverse effects in specific patient subgroups. Designed and managed by specialized health care professionals, PsoReg will enroll all psoriasis patients on systemic treatment to allow a fair comparison of old versus new-generation psoriasis treatments. PsoReg will even create benchmark data for quality assurance of the medical service. A web-based design allows real-time pharmacovigilance and enables the registry to assist clinicians in their day-to-day management of psoriasis patients. In this way PsoReg can become an integrated part of tomorrow’s dermatology.

show abstract

Psoriasis Therapy in Real Life: The Need for Registries

Cited by 54 publications

References 15 publications

Association between Psoriasis and the Metabolic Syndrome

Association between Psoriasis and the Metabolic Syndrome

Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies

PsoReg – The Swedish Registry for Systemic Psoriasis Treatment

Contact Info

Product

Resources

About